1-[(4-Chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine;hydron;dichloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(4-Chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine;hydron;dichloride
• 化学式: C25H29Cl3N2
• mdl: MFCD00058199
• 分子量: 463.9
• InChiKey: VCTHNOIYJIXQLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.39
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  6.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES
  申请人：Lal Bansi

  公开号：US20110172425A1

  公开（公告）日：2011-07-14

  The present invention relates to a novel water based process for the preparation of substituted diphenylmethyl piperazines of Formula I and pharmaceutically acceptable salts wherein X 1 and X 2 represent independently a hydrogen, a halogen, a straight or branched chain lower alkyl, alkoxy or a hydroxyl radical and R is selected from groups such as acyl, alkyl, alkenyl, aralalkyl, aralalkenyl aralkyl, and aralalkenyl or aralkenyl hydroxyalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl or its derivative comprising, reacting a compound of Formula II, with a compound of formula R—X where R is as defined above and X is suitable leaving group which includes halides, but not limiting use of other leaving groups such as tosylate, mesylate and activated acid groups such as acyl halide, anhydrides, mixed anhydrides etc. using water as a solvent, in presence of a catalyst and a base, at 25-100° C.;

  本发明涉及一种用水为基础的新型过程，用于制备化合物I的取代二苯甲基哌嗪及其药用盐，其中X1和X2分别代表氢、卤素、直链或支链低碳基、烷氧基或羟基基团，R选自酰基、烷基、烯基、芳基烷基、芳基烯基、芳基、芳基烯基或芳基羟基烷基、芳基氧基烷基、烷氧基烷基、氨基烷基或其衍生物等，包括将化合物II与化合物R-X反应，其中R如上定义，X是适当的离去基团，包括卤素等卤素，但不限于其他离去基团，如对甲苯磺酸酯、甲磺酸酯和活化酸基团，如酰卤、酸酐、混合酸酐等，使用水作为溶剂，在催化剂和碱的存在下，在25-100°C条件下进行。
• Small molecule toll-like receptor (TLR) antagonists
  申请人：Lipford B. Grayson

  公开号：US20050119273A1

  公开（公告）日：2005-06-02

  The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.

  本发明提供了用于调节通过Toll样受体信号传导的方法和组合物。该方法涉及使用含有至少两个环的核心结构的小分子与表达TLR的细胞接触。其中某些化合物是4-主氨基喹啉。许多化合物和方法特别适用于抑制涉及至少一个TLR9、TLR8、TLR7和TLR3的免疫刺激。该方法可用于治疗自身免疫、炎症、过敏、哮喘、移植排斥、移植物抗宿主病、感染、败血症、癌症和免疫缺陷。
• Controlled release composition comprising a sustained release layer and a fast release layer
  申请人：JOHNSON & JOHNSON CONSUMER COMPANIES, INC.

  公开号：EP1110541A1

  公开（公告）日：2001-06-27

  The present invention provides a composition comprising a sustained release layer and a fast release layer. The sustained release layer comprises a water-soluble polymer and a first pharmaceutically active agent. The fast release layer comprises a matrix forming agent and a second pharmaceutically active agent. Generally, the composition provides fast and sustained (or controlled) release of a pharmaceutically active agent for at least 6 hours and preferably for at least 1 to 3 days. The composition may be incorporated into a dosage unit form, such as a vaginal insert. The compositions are prepared by freeze-drying.

  本发明提供了一种由缓释层和速释层组成的组合物。缓释层包括水溶性聚合物和第一种药物活性剂。快速释放层包括基质形成剂和第二种药物活性剂。一般来说，该组合物可提供至少 6 小时，最好是至少 1 到 3 天的快速和持续（或控制）释放药用活性剂。该组合物可加入剂量单位形式中，如阴道插入物。组合物通过冷冻干燥制备。
• CYP2J2 antagonists in the treatment of pain
  申请人：Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.

  公开号：EP2985036A2

  公开（公告）日：2016-02-17

  The present invention pertains to novel treatments of neuropathic pain; in particular chemotherapy induced peripheral neuropathic pain (CIPNP). The invention provides antagonists cytochrome P450 epoxygenases (CYP), and more specifically antagonists of CYP2J2, as therapeutics for use in the treatment of neuropathic pain such as CIPNP. CYP2J2 antagonists were identified to alleviate CIPNP in-vivo, and therefore are provided additionally in combination with chemotherapeutics for the treatment of diseases such as cancer or other proliferative disorders. The CYP2J2 antagonists reduce chemotherapeutic induced pain and therefore allow for a higher dosing of the chemotherapeutic during cancer treatment. In addition the invention relates to the use of CYP2J2 agonists, or metabolites of CYP2J2, for sensitizing TRPV1. In this context the invention proposes to use combinations of CYP2J2 agonist or metabolites and transient receptor potential vanilloid 1 (TRPV1) agonists to treat disorders that respond to TRPV1 agonists, such as neuropathic pain.

  本发明涉及神经病理性疼痛的新型治疗方法，特别是化疗诱导的外周神经病理性疼痛（CIPNP）。本发明提供了细胞色素 P450 环氧酶（CYP）拮抗剂，更具体地说是 CYP2J2 拮抗剂，作为治疗神经性疼痛（如 CIPNP）的药物。经鉴定，CYP2J2拮抗剂可在体内缓解CIPNP，因此还可与化疗药物联合使用，用于治疗癌症或其他增殖性疾病等疾病。CYP2J2 拮抗剂能减轻化疗引起的疼痛，因此在癌症治疗过程中可以加大化疗剂量。此外，本发明还涉及 CYP2J2 激动剂或 CYP2J2 代谢物对 TRPV1 增敏的用途。在这种情况下，本发明建议使用 CYP2J2 激动剂或代谢物与瞬时受体潜在香草素 1（TRPV1）激动剂的组合来治疗对 TRPV1 激动剂有反应的疾病，如神经性疼痛。